熊本大学
生命資源研究・支援センター
遺伝子実験施設
熊本市本荘２－２－１
Tel : (096) 373-6501, FAX : (096)373-6502
２００３年 ７月 ７日 更新
|
アクティブボード・２００３年６月研究発表を行った学会；アメリカ臨床腫瘍学会２００３年５月２９日～６月５日（シカゴ） タイトル；各種ヒト癌組織における接着分子CD44の細胞外切断の解析 発表者；岡本 勇 氏 （熊本大学 熊本大学大学院医学薬学研究部 呼吸器病態学分野） Abstract； Cell surface adhesion molecules are crucial for the development and/or pathogenesis of various diseases including cancer. CD44 has received much interest as a major adhesion molecule that is involved in tumor progression. We have previously demonstrated that the ectodomain of CD44 undergoes proteolytic cleavage by membrane-associated metalloproteases in various tumor cell lines. The remaining membrane-bound CD44 cleavage product can be detected using antibodies against the cytoplasmic domain of CD44 (anti-CD44cyto Ab). However, the cleavage of CD44 in primary human tumors has not been investigated. Using Western blots with anti-CD44cyto Ab to assay human tumor tissues, we show that the CD44 cleavage product can be detected in 58% (42 of 72) of gliomas but not in normal brain. Enhanced CD44 cleavage was also found in 67% (28 of 42) of breast carcinomas, 45% (5 of 11) of non-small cell lung carcinomas, 90% (9 of 10) of colon carcinomas and 25% (3 of 12) of ovarian carcinomas. Tumors expressing a CD44 splice variant showed a significantly higher incidence of enhanced CD44 cleavage. The wide prevalence of CD44 cleavage suggests that it plays an important role in the pathogenesis of human tumors. |